# A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV

> **NCT06206720** · PHASE2 · COMPLETED · sponsor: **Vigonvita Life Sciences** · enrollment: 60 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infection

## Interventions

- **DRUG:** Deuremidevir Hydrobromide for Suspension
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06206720
- **Lead sponsor:** Vigonvita Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-31
- **Primary completion:** 2025-06-16
- **Final completion:** 2025-06-16
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06206720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06206720, "A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06206720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*